All In Biotech

Drug Trial Radar · NCT06808477

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

A Randomized, Blinded, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 in HVs and Adult Patients With AD

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 237 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

237

Planned (sponsor's estimate)

Start

Feb 27, 2025

Primary completion

Feb 28, 2027

Study completion Feb 28, 2027

Sponsor

Lead sponsor
Bambusa TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 72 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

Conditions

  • Atopic Dermatitis

Interventions

  • BBT001Drug

    BBT001 will be administered

  • PlaceboDrug

    Placebo will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events following single and multiple administration of BBT001Time frame: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
  2. Number of participants with change in serum blood parametersTime frame: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
  3. Number of participants with change in vital sign measurements following treatment administration.Time frame: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
  4. Number of participants with change in physical examination following treatment administration.Time frame: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
  5. Number of participants with change in 12-lead ECG readingsTime frame: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Locations

14 sites in 4 countries. Site status is shown where the registry gives one.

  • First OC Dermatology

    Irvine, California · Recruiting

  • OptiSkin Medical

    New York, New York · Recruiting

  • Equity Medical, LLC

    The Bronx, New York · Recruiting

  • Fremantle Dermatology

    Fremantle, Western Australia, Australia · Recruiting

  • Linear Clinical Research

    Perth, Western Australia, Australia · Completed

  • Optimal Clinical Trials Ltd - Christchurch

    Christchurch, New Zealand · Recruiting

  • Pacific Clinical Research Network (PCRN) Wellington

    Upper Hutt, New Zealand · Recruiting

  • Optimal Clinical Trials Central Auckland

    Grafton, Auckland, New Zealand · Recruiting

  • Aotearoa Clinical Trials

    Otahuhu, Auckland, New Zealand · Withdrawn

  • Pacific Clinical Research Network (PCRN) - Auckland

    Takapuna, Auckland, New Zealand · Recruiting

  • Wojewódzki Specjalistyczny Szpital im. Dr. Wł. Biegańskiego w Łodzi

    Lodz, Poland · Recruiting

  • Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie

    Rzeszów, Poland · Recruiting

  • Państwowy Instytut Medyczny MSWiA

    Warsaw, Poland · Recruiting

  • Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska

    Wroclaw, Poland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.